BAM
BOLD

Belpointe Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Belpointe Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,500
Closed -$297K – 659
2018
Q3 		$297K Hold
7,500
– – 0.05% 361
2018
Q2 		$287K Sell
7,500
-1,500
-17% -$55.6K 0.08% 271
2018
Q1 		$270K Buy
+9,000
New +$305K 0.08% 266

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Belpointe Asset Management's BOLD Position: Q4 2018 in Review

Belpointe Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2018, closing a stake of 7,500 shares — an estimated $297K sold.

Belpointe Asset Management first reported a position in BOLD in Q1 2018 and held it in 3 quarters. The position peaked at $297K in Q3 2018. 126 funds tracked by Wall St. Rank hold BOLD as of Q4 2018.

  • Belpointe Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Belpointe Asset Management sold 7,500 Audentes Therapeutics, Inc shares in Q4 2018, an estimated $297K.
  • Belpointe Asset Management first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 3 quarters.
  • Belpointe Asset Management's Audentes Therapeutics, Inc position peaked at $297K in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2018.

Based on Belpointe Asset Management's 13F filing for Q4 2018, filed 6 Mar 2019.